Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.
포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.
터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
FDA grants priority review for full approval of TARPEYO for the treatment of IgA Nephropathy PR Newswire STOCKHOLM, Aug. 18, 2023 STOCKHOLM, Aug...
Interim Report Q2, 2023: Calliditas Therapeutics PR Newswire STOCKHOLM, Aug. 17, 2023 Filing for full approval of TARPEYO STOCKHOLM, Aug. 17...
Calliditas Therapeutics announces full results from the NefIgArd Phase 3 trial published in The Lancet PR Newswire STOCKHOLM, Aug. 15, 2023...
Calliditas announces supportive interim data from Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib PR...
Calliditas Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Full Approval of TARPEYO® PR...
Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ) PR Newswire STOCKHOLM, May 30, 2023 STOCKHOLM, May 30, 2023...
Calliditas Therapeutics: Interim Report Q1, 2023 PR Newswire STOCKHOLM, May 16, 2023 STOCKHOLM, May 16, 2023 /PRNewswire/ -- Strong eGFR Data...
Calliditas Announces Late-Breaking Presentations at the 60th European Renal Association (ERA) Congress 2023 PR Newswire STOCKHOLM, May 5, 2023...
귀하가 조회한 주식이 이 박스에 나타나며 쉽게 최근 시세로 돌아갈 수 있습니다.
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관